Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)

By daniellenierenberg

MONT-SAINT-GUIBERT, Belgium, Dec. 01, 2023 (GLOBE NEWSWIRE) -- regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a transparency notification dated November 28, 2023, from Tolefi SA and related persons indicating that they have jointly crossed passively below the 15% threshold, holding 6,568,978 shares, or 14.997 % of the voting rights of the Company as of November 14, 2023.

Go here to see the original:
Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)

Related Post


categoriaSkin Stem Cells commentoComments Off on Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007) | dataDecember 4th, 2023

About...

This author published 4793 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024